Human keratin matrix use and wound healing outcomes in post-acute care of pressure ulcers: Evidence from a Bayesian real-world study

Mar 16, 2026
Human keratin matrix use and wound healing outcomes in post-acute care of pressure ulcers: Evidence from a Bayesian real-world study

In this real-world post-acute care cohort of patients with PUs, HKM use was associated with a high posterior probability of improved healing compared with SOC alone. These findings support HKM as an adjunctive therapy for complex or non-healing pressure ulcers in post-acute care settings.

Abstract

Aims: To evaluate the real-world effectiveness of a human keratin matrix (HKM) compared with standard of care (SOC) in promoting pressure ulcer (PU) healing among patients treated in post-acute care settings.

Methods: This observational comparative effectiveness study analyzed deidentified PU-level data from the LiftOff Registry, a national real-world database capturing post-acute wound care delivered in long-term acute care hospitals and skilled nursing facilities. PUs treated with HKM plus SOC were compared with those managed with SOC alone. Bayesian propensity score methods were used to reduce confounding and balance baseline demographic and clinical characteristics measured at PU identification. Healing—defined as complete epithelialization or closure—was modeled using Bayesian logistic regression with study arm and baseline PU stage as predictors. Treatment effects were summarized as posterior risk ratios (RR) with 95% highest density intervals (HDI) and posterior probabilities of benefit.

Results: Before matching, the SOC cohort included 9356 patients with 14,740 PUs (33.2% healed), while the HKM cohort included 58 patients with 81 PUs (54.3% healed). After matching, 161 PUs were analyzed (81 HKM; 80 SOC); most were Stage 3 or Stage 4. HKM treatment was associated with higher modeled probabilities of healing compared with SOC alone. The posterior mean RR for healing was approximately 1.6 (95% HDI ≈ 1.0–2.1), with a posterior probability of benefit (RR > 1) of approximately 99.4%.

Conclusion: In this real-world post-acute care cohort of patients with PUs, HKM use was associated with a high posterior probability of improved healing compared with SOC alone. These findings support HKM as an adjunctive therapy for complex or non-healing pressure ulcers in post-acute care settings.

Read The Article: https://internationaljournaloftissuerepair.com/index.php/ijtr/article/view/74

More Research

The Latest Research

Jan 2, 2026

Human keratin matrix in addition to standard of care accelerates healing of venous ulcers: a case series

Jan 2, 2026

International Consensus Document: Callular, Acellular, and Matrix-Like Products in Pressure Injuries

Based on these results, future studies should be conducted that further investigate the use of this novel human keratin matrix graft for the treatment of chronic DFUs.

Jan 2, 2026

A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin-based graft in the treatment of Wagner grade one non-healing diabetic foot ulcers

Based on these results, future studies should be conducted that further investigate the use of this novel human keratin matrix graft for the treatment of chronic DFUs.

Jan 1, 2026

Human Keratin Matrices Suppress Matrix Metalloproteinase Activity to Support Wound Healing

HKM is a unique and effective biomaterial for the treatment of chronic wounds through the modulation of wound MMP activity.

Oct 26, 2025

Real-world evaluation of cellular, acellular, and matrix-like products for pressure ulcers in the post-acute setting

This observational comparative effectiveness study analyzed de-identified data from the LiftOff Registry, a national database encompassing more than 18,000 patients and 23,000 pressure ulcers (PUs) treated in long-term acute care hospitals and skilled nursing facilities.

Sep 30, 2024
Wendy W. Weston
Wendy W. Weston

Retention processed placental membrane versus standard of care in treating diabetic foot ulcers

Diabetic foot ulcers (DFUs) are a severe complication for diabetic patients, significantly impacting patient quality of life and healthcare system efficiency. Traditional standard of care (SOC) treatments are inadequate for many patients, necessitating the use of advanced wound care products, such as human placental membranes.

Sep 9, 2024
David G. Armstrong, Dennis P. Orgill, Robert D. Galiano, Paul M. Glat, Marissa J. Carter, Jason Hanft, Maria Surprenant, Adam L. Isaac, Charles M. Zelen
David G. Armstrong, Dennis P. Orgill, Robert D. Galiano, Paul M. Glat, Marissa J. Carter, Jason Hanft, Maria Surprenant, Adam L. Isaac, Charles M. Zelen

A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin-based graft in the treatment of Wagner grade one non-healing diabetic foot ulcers

Diabetic foot complications that lead to lower extremity amputations pose a significant challenge to the entire global health system.

Jun 4, 2024
Zwelithini Tunyiswa, Robert G. Frykberg
Zwelithini Tunyiswa, Robert G. Frykberg

Assessing placental membrane treatment efficiency in diabetic foot ulcers: Processing for retention versus lamination

Diabetic foot ulcers are a severe complication in diabetic patients, significantly impact healthcare systems and patient quality of life, often leading to hospitalization and amputation.